Somatuline Predictive Factors in Acromegaly and NET | NCT01840449 | Trialant

Somatuline Predictive Factors in Acromegaly and NET | NCT01840449 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Neuroendocrine Tumours		The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.	Drug: Somatuline Autogel® 60, 90 or 120 mg
Acromegaly		The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.	Drug: Somatuline Autogel® 60, 90 or 120 mg

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)		Baseline and 1 year

Secondary Outcomes

Measure	Description	Time Frame
Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)		Baseline and 2 years

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
34293802	Derived	Rinke A, Maintz C, Muller L, Weber MM, Lahner H, Pavel M, Saeger W, Houchard A, Ungewiss H, Petersenn S. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. Exp Clin Endocrinol Diabetes. 2021 Jul;129(7):500-509. doi: 10.1055/a-1342-2755. Epub 2021 Jul 22.

Condition Browse Module